DDInter580 DDInter927
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Dofetilide {u} (Compound) resembles {v} (Compound) Dronedarone
Dofetilide {u} (Compound) resembles {v} (Compound) Rosiglitazone
Dofetilide {u} (Compound) binds {v} (Gene) KCNH2
Dofetilide {u} (Compound) upregulates {v} (Gene) CASP7
Dofetilide {u} (Compound) downregulates {v} (Gene) CDCA4
Dofetilide {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troglitazone
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Dofetilide (Compound) resembles Dronedarone (Compound)
Dofetilide (Compound) resembles Rosiglitazone (Compound)
Dofetilide (Compound) binds KCNH2 (Gene)
Dofetilide (Compound) upregulates CASP7 (Gene)
Dofetilide (Compound) downregulates CDCA4 (Gene)
Dofetilide (Compound) causes Dyspnoea (Side Effect)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide